Primary effusion lymphoma (PEL) is a rare mature B-cell non-Hodgkin's lymphoma arising in body cavities and presenting with effusions. It has been described predomi- 
| INTRODUC TI ON
Primary effusion lymphoma (PEL) is a rare non-Hodgkin's lymphoma (NHL) classified by the World Health Organization as a mature B-cell neoplasm. 1 It manifests as an exudative effusion in a body cavity, such as the pleural space or the peritoneum, without any identifiable tumor masses or lymphadenopathy and is causally linked to the Human Herpesvirus-8 (HHV-8) . 2 PEL is described predominantly in patients with the acquired immunodeficiency syndrome (AIDS). [2] [3] [4] Rarely, it has also been reported in persons not infected with the human immunodeficiency virus (HIV), specifically those with suppressed immunity following solid organ transplantation (SOT). [5] [6] [7] [8] [9] [10] [11] [12] We present an unusual case of PEL in an HIV-negative patient with a history of treated Kaposi's sarcoma (KS) who developed PEL following orthotopic heart transplantation (OHT).
| C A S E DE SCRIP TI ON
A 63-year-old Black man born in Haiti presented with one week of dyspnea, orthopnea, and swelling of the lower extremities. He denied subjective fever, cough, chest pain, weight loss, and night sweats. There was no history of sick contacts or recent travel. His Table 2 ). The patient then underwent bone marrow biopsy, and the findings were consistent with involvement by PEL.
Also noted was the reappearance of hyperpigmented lesions on his left sole, biopsy of which confirmed recurrence of KS ( Figure 3 ). In retrospect, it was noticed that his last two post-OHT serum HHV-8 polymerase chain reaction (PCR) results were positive, and repeat testing showed a further increase in the level of viremia (Figure 1 ). In hospital, he received one cycle of chemotherapy with cyclophosphamide, vincristine, prednisone, and brentuximab (doxorubicin was avoided due to its cardiac toxicity). 
| D ISCUSS I ON
Primary effusion lymphoma is a rare and aggressive mature large B-cell lymphoma, accounting for only about 4% of all AIDS-related lymphomas. 4 After its initial description in 1989 by Knowles et al, the other major milestone in the understanding of PEL came in 1995 when Cesarman et al linked it etiologically to infection by HHV-8. 11 The pathogenetic mechanism involves HHV-8's production of latent gene products such as latency-associated nuclear antigen-1 (LANA-1), viral cyclin (v-cyc), and viral FLICE inhibitory protein (vFLIP). Once incorporated into the target cell's genome, these products alter the cell cycle to increase proliferation and inhibit apoptosis, leading to clonal expansion and neoplastic transformation. 13 Although more than 70% of those with PEL exhibit coinfection with EBV, its role in PEL pathogenesis is yet to be defined. Currently, PEL diagnosis is based on the combination of morphological, immunophenotypical, molecular, and virological criteria. The treatment approach to PEL, which varies somewhat depending on the predisposing factors, is based on very scant evidence owing to the rarity of this condition. In the patient with AIDS, PEL is treated with systemic chemotherapy used for other forms of NHL such as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) along with antiretroviral therapy. HIV-positive cases of PEL carry a dismal prognosis. 3, 14 In SOT-associated PEL, in addition to chemotherapy, reduction of the level of immunosuppression is typically attempted.
Common practice is also to switch immunosuppression from calcineurin inhibition to mTOR inhibition with the use of an agent like sirolimus; however, cases of PEL have in fact been reported in those taking sirolimus after kidney transplantation. 7 As an adjunct to chemotherapy, Table 3 summarizes these three cases and compares them to the present one, which is the fourth. We believe that the following features are noteworthy about our patient relative to the previous reports: 
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